Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis
Arthritis Research & Therapy · 2024
DOI: 10.1186/s13075-024-03393-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Taejun Yoon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, BK21 Plus Project, College of Medicine, Yonsei University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Syndecan-1, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: faculty research grant of Yonsei University College of Medicine, CELLTRION PHARM, Inc. Chungcheongbuk-do, Republic of Korea, Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea.
Abstract (Originalsprache)
Objectives
This study investigated whether serum syndecan1 at diagnosis reflects activity at diagnosis and predicts poor outcomes during follow-up in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Methods
The study included 79 patients with AAV from the cohort of Korean patients diagnosed with AAV. AAV-specific indices, including the Birmingham vasculitis activity score (BVAS), five-factor score (FFS), 36-item short-form survey (SF-36) physical and mental component summary (PCS and MCS), and vasculitis damage index (VDI), were assessed. Laboratory data including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were also collected. The highest tertile and upper half of the BVAS were tentatively defined as having high AAV activity. Serum syndecan1 levels were measured in sera stored at diagnosis.
Results
Serum syndecan1 at diagnosis was significantly correlated with AAV activity and functional status, as assessed by BVAS, FFS, SF-36 PCS, MCS, and acute-phase reactants, including ESR and CRP. Patients with serum syndecan1 ≥ 76.1 ng/mL at diagnosis, and those with serum syndecan1 ≥ 60.0 ng/mL at diagnosis showed significantly higher risks for the highest tertile and the upper half of BVAS at diagnosis than those without, respectively. Patients with serum syndecan1 ≥ 120.1 ng/mL at diagnosis had a significantly higher risk for all-cause mortality during follow-up than those without, and further, exhibited a significantly lower cumulative patients’ survival rate than those without.
Conclusion
Serum syndecan1 at diagnosis may not only reflect AAV activity at diagnosis but may also be associated with all-cause mortality during follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Science, BK21 Plus Project, College of Medicine, Yonsei University, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi-do, Republic of Korea.
- Department of Rheumatology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Republic of Korea.
- Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722, Seoul, Republic of Korea. sangwonlee@yuhs.ac.
Förderung
- faculty research grant of Yonsei University College of Medicine
- CELLTRION PHARM, Inc. Chungcheongbuk-do, Republic of Korea
- Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea
Zitieren
APA
Yoon, T., Ha, J. W., Pyo, J. Y., Ko, E., Ahn, S. S., Song, J. J., Park, Y. B., & Lee, S. W. (2024). Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03393-8
Vancouver
Yoon T, Ha JW, Pyo JY, Ko E, Ahn SS, Song JJ, et al. Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03393-8
BibTeX
@article{Yoon2024,
author = {Yoon, Taejun and Ha, Jang Woo and Pyo, Jung Yoon and Ko, Eunhee and Ahn, Sung Soo and Song, Jason Jungsik and Park, Yong-Beom and Lee, Sang-Won},
title = {Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis},
journal = {Arthritis Research & Therapy},
year = {2024},
doi = {10.1186/s13075-024-03393-8}
}
EUVIMED